Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.

摘要: Statins (HMG-CoA reductase inhibitors) may decrease inflammation in postacute Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA) and promote vascular remodeling. There are limited data on their safety young children. Twenty patients with CAAs after KD (median CAA z-score = +25) were treated 5/10 mg atorvastatin daily for a median of 2.5 years (range 0.5–6.8) starting at 2.3 0.3–8.9) acute age 9.3 [range 0.7–14.3]). Compliance treatment was excellent: only one patient reported minor side effects (joint pain, no change medication). Average total cholesterol before 3.73 ± 0.84 mmol/L 3.21 0.46 (relative −14 %, p 0.02); low-density lipoprotein 1.99 0.76 1.49 0.27 −20 0.04); high-density 1.39 0.36 1.30 −4 0.35); triglycerides 0.71 0.28 0.18 −5 0.38). Nine 20 (45 %) experienced least 1 episode hypocholesterolemia (total 500 U/L). Serial measurements age- sex-specific percentiles weight (estimated change: 1.4 [2.7] % per year, 0.60), height −3.2 [3.2] 0.32), body mass index 1.0 [2.9] 0.73) showed association between anthropomorphic growth treatment. Atorvastatin use very children is safe but should be closely monitored.